IDEXX Laboratories Stock Price, News & Analysis (NASDAQ:IDXX)

$156.60 1.35 (0.87 %)
(As of 12/17/2017 07:02 AM ET)
Previous Close$156.60
Today's Range$155.16 - $157.99
52-Week Range$113.92 - $173.01
Volume1.05 million shs
Average Volume459,111 shs
Market Capitalization$13.66 billion
P/E Ratio52.73
Dividend YieldN/A
Beta0.42

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Veterinary Medical Equipment & Supplies
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Debt-to-Equity Ratio-12.48%
Current Ratio0.95%
Quick Ratio0.77%

Price-To-Earnings

Trailing P/E Ratio52.73
Forward P/E Ratio48.33
P/E Growth2.37

Sales & Book Value

Annual Sales$1.78 billion
Price / Sales7.69
Cash Flow$3.42 per share
Price / Cash45.80
Book Value($1.21) per share
Price / Book-129.42

Profitability

Trailing EPS$3.09
Net Income$222.04 million
Net Margins14.55%
Return on Equity-336.64%
Return on Assets16.63%

Miscellaneous

Employees7,365
Outstanding Shares87,220,000

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its board has authorized a stock buyback program on Sunday, June 4th 2017, which allows the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company's management believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its earnings results on Tuesday, October, 31st. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.74 by $0.05. The company had revenue of $492 million for the quarter, compared to analysts' expectations of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.62 earnings per share. View IDEXX Laboratories' Earnings History.

When will IDEXX Laboratories make its next earnings announcement?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY18 earnings guidance on Tuesday, October, 31st. The company provided EPS guidance of $3.50-$3.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.54. The company issued revenue guidance of $2.14-$2.18 billion, compared to the consensus revenue estimate of $2.14 billion.IDEXX Laboratories also updated its FY17 guidance to $3.22-$3.26 EPS.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2017?

6 analysts have issued 12 month price targets for IDEXX Laboratories' stock. Their forecasts range from $118.00 to $200.00. On average, they expect IDEXX Laboratories' stock price to reach $171.60 in the next twelve months. View Analyst Ratings for IDEXX Laboratories.

What are Wall Street analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "Over the last six months, IDEXX has been trading below the broader industry. Also, the company’s high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation is also a concern. On a positive note, IDEXX continues to demonstrate solid growth globally on strong international expansion. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX recently widened its cloud technology portfolio by adding rVetLink.  Solid organic revenue growth along with a raised guidance for 2017 buoy optimism." (10/24/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:

  • Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer (Age 60)
  • Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer (Age 54)
  • Giovani Twigge, Chief Human Resource Officer, Corporate Vice President (Age 53)
  • Jay Mazelsky, Executive Vice President (Age 56)
  • Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary (Age 58)
  • William T. End, Lead Independent Director (Age 69)
  • Bruce L Claflin, Independent Director (Age 65)
  • Stuart M. Essig Ph.D., Independent Director (Age 55)
  • Rebecca M. Henderson Ph.D., Independent Director (Age 56)
  • Daniel M. Junius, Independent Director (Age 64)

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include Neuberger Berman Group LLC (1.97%), Janus Henderson Group PLC (1.22%), Bank of New York Mellon Corp (1.10%), Old Mutual Global Investors UK Ltd. (0.95%), American Century Companies Inc. (0.82%) and Columbus Circle Investors (0.63%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Schwab Charles Investment Management Inc., JPMorgan Chase & Co., Ameriprise Financial Inc., Prudential Financial Inc., Janus Henderson Group PLC, First Trust Advisors LP and AXA. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?

IDEXX Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., American Century Companies Inc., Bank of New York Mellon Corp, Point72 Asset Management L.P., APG Asset Management N.V., Canada Pension Plan Investment Board, Assetmark Inc. and Allianz Asset Management GmbH. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDEXX Laboratories stock can currently be purchased for approximately $156.60.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $13.66 billion and generates $1.78 billion in revenue each year. The company earns $222.04 million in net income (profit) each year or $3.09 on an earnings per share basis. IDEXX Laboratories employs 7,365 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (IDXX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  424
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IDEXX Laboratories (NASDAQ:IDXX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.292.292.382.20
Ratings Breakdown: 2 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $171.60$171.60$157.17$128.60
Price Target Upside: 7.45% upside4.36% upside2.84% upside20.27% downside

IDEXX Laboratories (NASDAQ:IDXX) Consensus Price Target History

Price Target History for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ:IDXX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017AegisReiterated RatingSellLowView Rating Details
10/24/2017Stifel NicolausReiterated RatingBuy$185.00N/AView Rating Details
10/6/2017Canaccord GenuityReiterated RatingBuy$180.00N/AView Rating Details
8/23/2017Bank of AmericaUpgradeNeutral -> Buy$175.00LowView Rating Details
7/28/2017CL KingUpgradeNeutral -> Buy$200.00MediumView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
2/1/2016Piper Jaffray CompaniesReiterated RatingNeutral$73.00 -> $75.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

IDEXX Laboratories (NASDAQ:IDXX) Earnings History and Estimates Chart

Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ IDXX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018$0.73N/AView Earnings Details
10/31/2017Q3 2017$0.74$0.79$492.94 million$492.00 millionViewN/AView Earnings Details
8/1/2017Q2 2017$0.85$0.95$502.44 million$508.90 millionViewListenView Earnings Details
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

IDEXX Laboratories (NASDAQ:IDXX) Earnings Estimates

2017 EPS Consensus Estimate: $2.90
2018 EPS Consensus Estimate: $3.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.59$0.61$0.60
Q2 20173$0.82$0.88$0.85
Q3 20173$0.74$0.75$0.75
Q4 20173$0.67$0.74$0.71
Q1 20182$0.74$0.81$0.78
Q2 20182$1.05$1.09$1.07
Q3 20182$0.88$0.89$0.89
Q4 20182$0.77$0.83$0.80
(Data provided by Zacks Investment Research)

Dividends

Dividend History for IDEXX Laboratories (NASDAQ:IDXX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

IDEXX Laboratories (NASDAQ IDXX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.77%
Institutional Ownership Percentage: 86.80%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ IDXX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2017Giovani TwiggeInsiderSell2,000$156.07$312,140.00View SEC Filing  
11/16/2017Jonathan W AyersCEOSell18,000$153.61$2,764,980.00View SEC Filing  
11/14/2017Jonathan W AyersCEOSell18,000$148.35$2,670,300.00View SEC Filing  
11/7/2017Jonathan W AyersChairmanSell54,000$151.32$8,171,280.00View SEC Filing  
11/3/2017Jonathan W AyersCEOSell18,000$153.75$2,767,500.00View SEC Filing  
8/28/2017Jonathan W AyersChairmanSell13,000$150.79$1,960,270.00View SEC Filing  
8/23/2017Rebecca M HendersonDirectorSell5,156$153.29$790,363.24View SEC Filing  
8/22/2017Rebecca M HendersonDirectorSell2,578$152.86$394,073.08View SEC Filing  
8/16/2017Jonathan W AyersChairmanSell58,000$155.00$8,990,000.00View SEC Filing  
8/15/2017Jonathan W AyersCEOSell20,000$154.62$3,092,400.00View SEC Filing  
8/14/2017Jonathan W AyersCEOSell18,000$154.91$2,788,380.00View SEC Filing  
8/9/2017Jonathan W AyersChairmanSell17,000$154.54$2,627,180.00View SEC Filing  
8/8/2017Jonathan W. AyersChairmanSell18,000$155.22$2,793,960.00View SEC Filing  
8/3/2017Lawrence D KingsleyDirectorBuy2,000$151.76$303,520.00View SEC Filing  
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.00View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.00View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.00View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.00View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.00View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.36View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.00View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.48View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.16View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.00View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.00View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.32View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.88View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.00View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.88View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.00View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.08View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.10View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.00View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.00View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.00View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.24View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.00View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.00View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.00View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.00View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.00View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.80View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.52View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

IDEXX Laboratories (NASDAQ IDXX) News Headlines

Source:
DateHeadline
IDEXX Laboratories, Inc. (IDXX) Expected to Post Earnings of $0.73 Per ShareIDEXX Laboratories, Inc. (IDXX) Expected to Post Earnings of $0.73 Per Share
www.americanbankingnews.com - December 16 at 11:34 PM
IDEXX Laboratories (IDXX) Lowered to "Sell" at BidaskClubIDEXX Laboratories (IDXX) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - December 16 at 8:38 AM
IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : December 15, 2017IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : December 15, 2017
finance.yahoo.com - December 15 at 11:56 AM
ETFs with exposure to IDEXX Laboratories, Inc. : December 8, 2017ETFs with exposure to IDEXX Laboratories, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 3:36 PM
IDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : December 6, 2017IDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : December 6, 2017
finance.yahoo.com - December 6 at 3:36 PM
IDXX Crosses Above Average Analyst TargetIDXX Crosses Above Average Analyst Target
www.nasdaq.com - December 6 at 11:43 AM
IDEXX Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IDXX-US : December 5, 2017IDEXX Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IDXX-US : December 5, 2017
finance.yahoo.com - December 5 at 12:25 PM
IDEXX Laboratories, Inc. (IDXX) Insider Sells $312,140.00 in StockIDEXX Laboratories, Inc. (IDXX) Insider Sells $312,140.00 in Stock
www.americanbankingnews.com - December 4 at 9:02 PM
IDXX Makes Bullish Cross Above Critical Moving Average - NasdaqIDXX Makes Bullish Cross Above Critical Moving Average - Nasdaq
www.nasdaq.com - December 4 at 3:36 PM
Cramer Remix: Amazon may not be as powerful as it seemsCramer Remix: Amazon may not be as powerful as it seems
finance.yahoo.com - December 1 at 5:01 PM
Idexx Laboratories CEO: 'Blockbuster' pet care technology...Idexx Laboratories CEO: 'Blockbuster' pet care technology...
finance.yahoo.com - December 1 at 5:01 PM
$491.02 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter$491.02 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - November 30 at 11:04 AM
Looking for a Growth Stock? Why It is Time to Focus on IDEXX Laboratories (IDXX)Looking for a Growth Stock? Why It is Time to Focus on IDEXX Laboratories (IDXX)
finance.yahoo.com - November 29 at 11:27 AM
$0.73 EPS Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter$0.73 EPS Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - November 28 at 7:08 PM
ETFs with exposure to IDEXX Laboratories, Inc. : November 27, 2017ETFs with exposure to IDEXX Laboratories, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 5:25 PM
IDEXX Laboratories, Inc. (IDXX) Receives Consensus Recommendation of "Hold" from BrokeragesIDEXX Laboratories, Inc. (IDXX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 27 at 12:12 PM
Jonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) StockJonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock
www.americanbankingnews.com - November 16 at 10:33 PM
IDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 18,000 SharesIDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 18,000 Shares
www.americanbankingnews.com - November 16 at 10:33 PM
Cramers lightning round: This is your chance to get into up stock Idexx Labs - CNBCCramer's lightning round: This is your chance to get into 'up stock' Idexx Labs - CNBC
www.cnbc.com - November 15 at 1:22 AM
4 Top Growth Picks to Avoid Tax Tangle in MedTech4 Top Growth Picks to Avoid Tax Tangle in MedTech
finance.yahoo.com - November 14 at 8:15 PM
Cramers lightning round: This is your chance to get into up stock Idexx LabsCramer's lightning round: This is your chance to get into 'up stock' Idexx Labs
finance.yahoo.com - November 14 at 8:15 PM
ETFs with exposure to IDEXX Laboratories, Inc. : November 13, 2017ETFs with exposure to IDEXX Laboratories, Inc. : November 13, 2017
finance.yahoo.com - November 13 at 7:49 PM
Zacks: Brokerages Expect IDEXX Laboratories, Inc. (IDXX) Will Post Quarterly Sales of $491.02 MillionZacks: Brokerages Expect IDEXX Laboratories, Inc. (IDXX) Will Post Quarterly Sales of $491.02 Million
www.americanbankingnews.com - November 12 at 6:46 PM
Zacks: Brokerages Expect IDEXX Laboratories, Inc. (IDXX) to Announce $0.73 EPSZacks: Brokerages Expect IDEXX Laboratories, Inc. (IDXX) to Announce $0.73 EPS
www.americanbankingnews.com - November 10 at 3:38 AM
Jonathan W. Ayers Sells 54,000 Shares of IDEXX Laboratories, Inc. (IDXX) StockJonathan W. Ayers Sells 54,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock
www.americanbankingnews.com - November 7 at 6:28 PM
IDEXX Laboratories, Inc. (IDXX) CEO Sells $2,767,500.00 in StockIDEXX Laboratories, Inc. (IDXX) CEO Sells $2,767,500.00 in Stock
www.americanbankingnews.com - November 7 at 6:28 PM
Quant Score Make IDEXX Laboratories (IDXX) a BuyQuant Score Make IDEXX Laboratories (IDXX) a Buy
investorplace.com - November 7 at 5:09 PM
IDEXX Laboratories Target of Unusually Large Options Trading (IDXX)IDEXX Laboratories Target of Unusually Large Options Trading (IDXX)
www.americanbankingnews.com - November 5 at 3:18 AM
IDEXX Laboratories, Inc. :IDXX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017IDEXX Laboratories, Inc. :IDXX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017
finance.yahoo.com - November 4 at 1:53 AM
ETFs with exposure to IDEXX Laboratories, Inc. : November 3, 2017ETFs with exposure to IDEXX Laboratories, Inc. : November 3, 2017
finance.yahoo.com - November 4 at 1:53 AM
IDEXX Laboratories Inc (IDXX): Is It A Good Long Term Opportunity? - Yahoo FinanceIDEXX Laboratories Inc (IDXX): Is It A Good Long Term Opportunity? - Yahoo Finance
finance.yahoo.com - November 3 at 9:11 AM
IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : November 3, 2017IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : November 3, 2017
finance.yahoo.com - November 3 at 9:11 AM
IDEXX Laboratories, Inc. (IDXX) Given Average Rating of "Hold" by AnalystsIDEXX Laboratories, Inc. (IDXX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 2 at 6:08 PM
IDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term RevenueIDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term Revenue
www.fool.com - November 2 at 4:53 PM
Q4 2017 EPS Estimates for IDEXX Laboratories, Inc. Increased by Northcoast Research (IDXX)Q4 2017 EPS Estimates for IDEXX Laboratories, Inc. Increased by Northcoast Research (IDXX)
www.americanbankingnews.com - November 2 at 11:30 AM
Stocks To Watch: Idexx Laboratories Sees RS Rating Jump To 83Stocks To Watch: Idexx Laboratories Sees RS Rating Jump To 83
finance.yahoo.com - November 2 at 1:52 AM
Edited Transcript of IDXX earnings conference call or presentation 31-Oct-17 12:30pm GMTEdited Transcript of IDXX earnings conference call or presentation 31-Oct-17 12:30pm GMT
finance.yahoo.com - November 2 at 1:52 AM
IDEXX Laboratories, Inc. (IDXX) Announces Quarterly  Earnings Results, Beats Estimates By $0.05 EPSIDEXX Laboratories, Inc. (IDXX) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - November 1 at 3:50 PM
William Blair Equities Analysts Boost Earnings Estimates for IDEXX Laboratories, Inc. (IDXX)William Blair Equities Analysts Boost Earnings Estimates for IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - November 1 at 9:38 AM
FY2017 EPS Estimates for IDEXX Laboratories, Inc. (IDXX) Lifted by Northcoast ResearchFY2017 EPS Estimates for IDEXX Laboratories, Inc. (IDXX) Lifted by Northcoast Research
www.americanbankingnews.com - November 1 at 9:38 AM
IDEXX Laboratories Inc Reveals 25% Advance In Q3 Bottom LineIDEXX Laboratories Inc Reveals 25% Advance In Q3 Bottom Line
www.rttnews.com - October 31 at 9:49 PM
IDEXX Laboratories (IDXX) Q3 2017 Results - Earnings Call TranscriptIDEXX Laboratories (IDXX) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 31 at 9:49 PM
IDEXX Laboratories Announces Third Quarter ResultsIDEXX Laboratories Announces Third Quarter Results
finance.yahoo.com - October 31 at 9:49 PM
Idexx beats 3Q profit forecastsIdexx beats 3Q profit forecasts
finance.yahoo.com - October 31 at 9:48 PM
IDEXX Laboratories Inc (IDXX): Is It A Good Long Term Opportunity?IDEXX Laboratories Inc (IDXX): Is It A Good Long Term Opportunity?
finance.yahoo.com - October 31 at 9:48 PM
IDEXX Laboratories (IDXX) Beats on Q3 Earnings, View UpIDEXX Laboratories (IDXX) Beats on Q3 Earnings, View Up
finance.yahoo.com - October 31 at 9:48 PM
IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues MissIDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss
finance.yahoo.com - October 31 at 9:48 PM
IDEXX Laboratories, Inc. (IDXX) Releases FY18 Earnings GuidanceIDEXX Laboratories, Inc. (IDXX) Releases FY18 Earnings Guidance
www.americanbankingnews.com - October 31 at 9:55 AM
IDEXX Laboratories, Inc. (IDXX) Releases FY17 Earnings GuidanceIDEXX Laboratories, Inc. (IDXX) Releases FY17 Earnings Guidance
www.americanbankingnews.com - October 31 at 9:55 AM
The Humanization of Pets Has Changed the Industry -- Heres the Best Stock Pick - TheStreet.comThe Humanization of Pets Has Changed the Industry -- Here's the Best Stock Pick - TheStreet.com
www.thestreet.com - October 30 at 9:47 PM

SEC Filings

IDEXX Laboratories (NASDAQ:IDXX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IDEXX Laboratories (NASDAQ:IDXX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IDEXX Laboratories (NASDAQ IDXX) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.